Needham & Company Reiterates Bicycle Therapeutics (BCYC) at Buy, Focus Remains on BT8009
Tweet Send to a Friend
Needham & Company analyst Ami Fadia reiterated a Buy rating and $85.00 price target on Bicycle Therapeutics (NASDAQ: BCYC), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
